Skip to content

A multicenter, randomized, double-blind, placebo-controlled trial for Xiaoyao capsule in the improvement of sleep mood disorder of convalescence patients of novel coronavirus pneumonia (COVID-19)

Xiaoyao capsule improves COVID-19 convalescence sleep mood disorder in a randomized, double-blind, placebo-controlled, multicenter clinical study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003249
Enrollment
Unknown
Registered
2020-04-27
Start date
2020-04-20
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

Sponsors

Xiaogan Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. COVID-19 convalescent diagnostic criteria; 2. Cured and discharged patients more than 2 weeks; 3. Aged from 18 to 70 years; 4. Patients with sleep mood disorders such as restlessness, anxiety and sleep disorders were the main clinical manifestations, and those with two symptoms at the same time, or visual analogue scale (VAS) of single symptom >=4; 5. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with difficulty in taking oral drugs due to basic diseases; 2. Accompanied by severe basic diseases affecting survival, including uncontrolled clinically significant heart, lung, kidney, digestion, blood diseases, neuropsychiatric diseases, immune diseases, metabolic diseases, malignant tumors, and severe malnutrition; 3. Allergic constitution, allergic to the drugs involved in the treatment plan; 4. Pregnant or lactating women; 5. Mental state: unable to cooperate, suffering from mental illness, no self-knowledge, and unable to express clearly; 6. Participants in other clinical trials; 7. According to the judgment of the researcher, there will be patients with complicated enrollment or poor compliance, which will affect the efficacy and safety evaluation.

Design outcomes

Primary

MeasureTime frame
N/A;

Countries

China

Contacts

Public ContactYang Guiping

Xiaogan Traditional Chinese Medicine Hospital

1365431567@qq.com+86 15335748899

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026